The absorption, distribution, metabolism, and elimination of [3-14 C] 8-2 fluorotelomer alcohol (8-2 FTOH, C 7 F 15 14 CF 2 -CH 2 CH 2 OH) following a single oral dose at 5 and 125 mg/kg in male and female rats have been determined. Following oral dosing, the maximum concentration of 8-2 FTOH in plasma occurred by 1 h postdose and cleared rapidly with a half-life of less than 5 h. The internal dose to 8-2 FTOH, as measured by area under the concentration-time curve to infinity, was similar for male and female rats and was observed to increase in a dosedependent fashion. The majority of the 14 C 8-2 FTOH ( > 70%) was excreted in feces, and 37-55% was identified as parent. Less than 4% of the administered dose was excreted in urine, which contained low concentrations of perfluorooctanoate (~1% of total 14 C). Metabolites identified in bile were principally composed of glucuronide and glutathione conjugates, and perfluorohexanoate was identified in excreta and plasma, demonstrating the metabolism of the parent FTOH by sequential removal of multiple CF 2 groups. At 7 days postdose, 4-7% of the administered radioactivity was present in tissues, and for the majority, 14 C concentrations were greater than whole blood with the highest concentration in fat, liver, thyroid, and adrenals. Distribution and excretion of a single 125-mg/kg [3-14 C] 8-2 FTOH dermal dose following a 6-h exposure in rats was also determined. The majority of the dermal dose either volatilized from the skin (37%) or was removed by washing (29%). Following a 6-h dermal exposure and a 7-day collection period, excretion of total radioactivity via urine ( < 0.1%) and feces ( < 0.2%) was minor, and radioactivity concentrations in most tissues were below the limit of detection. Systemic availability of 8-2 FTOH following dermal exposure was negligible.
The presence of perfluorosulfonic acids and perfluorocarboxylic acids (PFCAs) in mammals and the environment has fueled a growing interest into the sources and biological fate of this class of chemistry (Ellis et al., 2003 (Ellis et al., , 2004 Moody et al., 2002; Olsen et al., 2003; Verreault et al., 2005) . Recently, the potential sources and fate of PFCAs have been discussed (Prevedouros et al., 2005) . Fluorotelomer-based substances have been proposed as a possible indirect source for PFCAs, since they may contain PFCAs as an unintended reaction byproduct and may also degrade to form PFCAs. Fluorotelomer alcohols (FTOHs) are a raw material comprising an even number of fluorinated carbons appended to an ethanol moiety (F(CF 2 ) x C 2 H 4 OH; x ¼ 6, 8, 10) and are used in the manufacture of products with unique surface properties used in a variety of industrial and consumer applications (Baker and Rao, 1994; Kissa, 2001) . 8-2 FTOH is the homologue produced in the largest volume. In 2000-2002, global production of perfluoroalkyl iodide, which is used to make fluorotelomerbased products, exceeded 5000 metric tons (Telomer Research Program, 2002) .
The subchronic and developmental/reproductive toxicities of 8-2 FTOH (DuPont-9478, unpublished; Mylchreest et al., 2005b) and of a commercial mixture containing 6-2, 8-2, and 10-2 FTOH (Ladics et al., 2005; Mylchreest et al., 2005a) have been reported. In the subchronic 90-day oral study, where 8-2 FTOH was administered at 1, 5, 25, and 125 mg/kg/day, the no observable effect level for male and female rats was 5 and 25 mg/kg/day, respectively, and was based on liver necrosis and nephropathy unpublished) . Hepatic boxidation, a measure of peroxisome proliferation, was increased in females at 25 mg/kg/day and in males and females at 125 mg/ kg/day; plasma and urine fluoride concentrations, as measured using a fluoride-selective electrode, were significantly increased in males and females at the 125-mg/kg/day dose level. The developmental toxicity study in rats reported that 8-2 FTOH was not a selective developmental toxin (Mylchreest et al., 2005b) .
The metabolism of 8-2 FTOH in male rats following a 400mg/kg single oral dose and analysis of plasma at 6 h postdose have been reported (Hagen et al., 1981) . Perfluorooctanoate (PFO), the disassociated form of the free acid, 8-2 fluorotelomer acid (CF 3 (CF 2 ) 6 CF 2 CH 2 COOH; 8-2 FTA), and 8-2 fluorotelomer unsaturated acid (CF 3 (CF 2 ) 6 CF¼CHCOOH; 8-2 FTUA) were identified in plasma. More recently, Kudo et al. (2005) examined the effects of 8-2 FTOH dietary intake in mice at 0, 0.025, 0.05, 0.1, and 0.2% (wt/wt) and reported evidence of a dose-and duration-dependent liver enlargement caused by peroxisome proliferation. PFO, perfluorononanoate (PFN), 8-2 FTA, and two unidentified metabolites were observed in liver and plasma.
The metabolic fate of 8-2 FTOH in rat hepatocytes has been reported to occur primarily by direct conjugation of parent to form O-glucuronide and O-sulfate (Martin et al., 2005) . A transient 8-2 fluorotelomer aldehyde (CF 3 (CF 2 ) 7 CH 2 CH¼O; 8-2 FTAL) and the presence of 8-2 FTA, 8-2 FTUA, 7-3 Acid (CF 3 (CF 2 ) 6 CH 2 CH 2 COOH), unsaturated 7-3 Acid (CF 3 (CF 2 ) 6 CH¼ CHCOOH; 7-3 uAcid), and glutathione (GSH) conjugates of the 8-2 FTOH unsaturated aldehyde (8-2 uFTALÁGS), 8-2 FTUA (8-2 FTUAÁGS), and the reduced form the 8-2 uFTALÁGS (8-2ÁuFTOHÁGS) were also observed. Martin et al. (2005) also reported results from a single ip 400-mg/kg dose to male rats and analysis of plasma at 6 h postdose, confirming the observation of PFO, 8-2 FTA, and 8-2 FTUA by Hagen et al. (1981) .
The metabolism of 8-2 FTOH in sludge, soils, and groundwater sediment has been studied to determine whether and to what extent PFCAs, including PFO, would be formed (Dinglasan et al., 2004; Wang et al., 2005a,b) . These studies report that the relative amount of PFO produced from 8-2 FTOH metabolism was minor (less than 6%), suggesting that microbial metabolism of 8-2 FTOH is unlikely a principal source for PFO in the environment. A detailed microbial metabolic pathway for 8-2 FTOH has been proposed (Wang et al., 2005b) .
Thus far, 8-2 FTOH in vivo rat metabolism experiments have been limited in scope, generally qualitative, and lacking a quantitative measure of absorption, distribution, metabolism, and elimination (ADME) and an answer to the fundamental question of how much PFO is produced. The goal of the present research was to quantitatively determine 8-2 FTOH ADME in male and female rats following a single oral dose and also the absorption, distribution, and excretion following a 6-h dermal exposure in the rat utilizing radiolabeled 8-2 FTOH (DuPont-6997, unpublished).
MATERIALS AND METHODS
Chemicals. The test material, 1H,1H,2H,2H-perfluorodecanol (CF 3 (CF 2 ) 7 CH 2 CH 2 OH; 8-2 FTOH; CASN 678-39-7), was supplied by E.I. du Pont de Nemours and Company (Wilmington, DE). The sample had a purity of 99.2%. The primary impurity (0.8%) was unsaturated 8-2 FTOH (CF 3 (CF 2 ) 6 CF¼ CHCH 2 OH; 8-2 uFTOH). 8-2 FTOH is relatively insoluble in water (148 lg/l) and has a vapor pressure of 3 Pa (~0.02 mm Hg) at 22°C (Krusic et al., 2005) .
Radiolabeled [3-14 C] 8-2 FTOH was synthesized by Perkin-Elmer Life and Analytical Sciences, Inc. (Boston, MA). The radiolabeled test material had a specific activity of 54.3 mCi/mmol and a radiochemical purity of > 98%. The material was stored at ÿ70°C. 8-2 Fluorotelomer acid (CF 3 (CF 2 ) 7 CH 2 COOH; 8-2 FTA) and 8-2 FTUA, were provided by E.I. du Pont de Nemours and Company. The PFCAs, perfluorohexanoic acid, perfluoroheptanoic acid, perfluorooctanoic acid, and perfluorononanoic acid were purchased from Sigma Aldrich (St. Louis, MO), and their purity was > 95%.
Media and reagents for the hepatocyte isolations were obtained from Invitrogen (Carlsbad, CA).
Animals. Male and female Crl:CD (SD)IGS BR rats, including jugular vein-and bile duct-cannulated animals, were obtained from Charles River Laboratories, Inc. (Raleigh, NC) . At the time of dosing, rats were approximately 6-8 weeks of age.
Oral dosing. Three main oral gavage-dosing experiments were conducted: material balance, biliary elimination, and plasma kinetics. Four male and four female rats per dose level per experiment were given single oral gavage doses formulated with [3-14 C] 8-2 FTOH at 5 and 125 mg/kg. The dose levels were selected to match the dose levels used in the rat subchronic toxicity study unpublished) . Methylcellulose (0.5% wt/vol) was selected as the vehicle for consistency with the 90-day subchronic study and to facilitate comparisons between oral and dermal exposure routes. All rats were fasted for approximately 16 h prior to oral dosing. Following dosing, rats for the material balance experiment were housed in glass metabolism units, and excreta was collected on dry ice at 6, 12, and 24 h and at 24-h intervals thereafter through 168 h. At the end of the collection period, rats were anesthetized by exposure to carbon dioxide and sacrificed by exsanguination via cardiac puncture. Selected tissues were collected for analysis of total radioactivity. Rats for the biliary elimination experiment were received from the supplier with a cannula surgically implanted in the bile duct. Rats were housed one per metabolism unit and provided with isotonic dextrose/KCl/NaCl as the sole source of drinking fluid for the duration of the in-life phase. Bile was collected on dry ice at approximately 6, 12, and 24 h and every 24 h until sacrifice (120 h postdose).
Rats for the plasma kinetic experiment were received from the supplier with a cannula inserted in the jugular vein. Following fasting, each rat received a single oral dose formulated with [3-14 C] 8-2 FTOH. Following dosing, serial blood samples were collected from the jugular vein cannula, and alternatively from the orbital sinus or lateral tail vein and placed into tubes containing EDTA. Whole-blood samples were collected predose and at approximately 5, 15, and 30 min and 1, 2, 4, 6, 12, and 24 h postdose and at 24-h intervals thereafter until 168 h. Serial whole-blood samples were kept on wet ice, and plasma was separated from the red cell fraction by centrifugation. Plasma was stored frozen at < ÿ10°C prior to analysis.
In a separate (supplemental) experiment, a single male and female rat were administered a 125-mg/kg single oral dose of 8-2 FTOH fortified with [3-14 C] 8-2 FTOH and serial blood samples collected at 1, 2, 4, 8, 24, and 48 h. Plasma was separated from the red cell fraction by centrifugation and pooled (1-24 h) for metabolite profiling and identification.
Dermal exposure. The study comprised a single exposure group of three male and three female rats. 8-2 FTOH fortified with [3-14 C] 8-2 FTOH was administered at a dose rate of 125 mg/kg in 0.5% methylcellulose. On the day prior to dosing, the back and shoulder area were clipped free of hair and washed with a 2% Ivory soap solution in water. Following shaving and washing, a glass O-ring with an internal exposure area of approximately 5.3 cm 2 was glued to the shaved skin with Scotch Brand Crazy Glue Gel and the area covered with gauze and wrapped with Coban. Rats were fitted with cervical collars and acclimated overnight prior to dosing. At dosing, rats were anesthetized with Isoflurane, and the dermal dose was applied at a rate of approximately 10 ll/cm 2 to the area within the glass O-ring. Immediately following administration of the dose, the dose site was covered with an airtight, organic volatile trap containing untreated, granular activated charcoal, size 8-20 mesh (Sigma 342 FASANO ET AL.
Chemical Company, St. Louis, MO). At the conclusion of the 6-h exposure period, the charcoal trap was removed and immediately placed into a glass container with ethanol, and the dose site was washed with natural sponge soaked in ethanol (use of a 2% soap and water solution had previously been shown to result in low recovery of radiolabeled 8-2 FTOH). Rats were then fitted with a fresh charcoal trap and body wrap and returned to their metabolism units. At 24 h postdose, the charcoal trap was again collected, placed into ethanol, and a fresh charcoal trap applied, which remained in place until termination at 168 h postdose. Urine and feces were collected on dry ice at approximately 6 (end of exposure), 12, and 24 h following dosing and at 24-h intervals thereafter until sacrifice at 168 h. At sacrifice, rats were anesthetized by exposure to carbon dioxide, exsanguinated, and tissues collected for analysis.
Rat hepatocyte in vitro metabolism. In order to support the identification of metabolites from the in vivo experiments, 8-2 FTOH was incubated with isolated rat hepatocytes. Rat hepatocytes were prepared by a modification of the method from Seglen (1976) with a two-stage collagenase perfusion using commercially available reagents. The isolated cells were diluted to a final concentration of approximately 5 3 10 6 cells/ml, and [3-14 C] 8-2 FTOH was added to a concentration of 50lM in a final volume of 1 ml. The sample was incubated at 37°C for 2 h and terminated by the addition of acetonitrile (vol/ vol). The sample was filtered (0.45 lm) and used for metabolite identification.
Sample collection, processing, and 14 C analysis. Quantitative analysis of samples from the oral (material balance, plasma kinetic, and biliary elimination) and dermal experiments was performed by taking representative aliquots, at least in duplicate or in triplicate when sufficient sample was available, and analyzing by either direct analysis (i.e., liquid samples) using liquid scintillation counting (LSC) or by combustion analysis (i.e., semisolid and solid samples) using a Packard Tri-Carb Automatic Sample Oxidizer followed by LSC using Packard Tricarb 2500TR liquid scintillation counter (Meriden, CT).
The application skin site and nondosed skin samples from the dermal exposure experiment were digested in Soluene-350 (Perkin-Elmer Life and Analytical Sciences, Inc.) and analyzed for total radioactivity by LSC.
Quantitative analysis of plasma for 8-2 FTOH. Plasma was thawed at room temperature and a 50-ll aliquot removed with an airtight syringe. The sample was injected into a 2-ml glass vial insert, heated to approximately 50°C for 10 min, and the headspace extracted for 5 min using a 100-lm film thickness polydimethylsiloxane solid-phase microextraction fiber. Following extraction, the fiber was desorbed at 250°C for 1 min and analyzed using an Agilent Gas Chromatography (GC) HP 6890 Series/Mass Selective Detection (Agilent Technologies, Palo Alto, CA) with a Gerstel MultiPurpose Sampler (Gerstel Inc., Baltimore, MD). Separation was achieved using a DB-5MS Capillary Column, 30 m 3 0.250 mm 3 1.0 lm (J&W Scientific, Folsom, CA) and an inlet program temperature of 250°C at 12.5 pounds per square inch (psi) with a total flow of 81 ml/min operated in splitless mode. The mass spectrometer (MS) detector was operated in a single-ion monitoring mode with source temperature of 250°C.
Quantitative analysis of plasma for PFO and 8-2 FTA. Plasma was thawed at room temperature and a 50-ll aliquot applied to an Isolute array protein precipitation plate (Jones Chromatography, Lakewood, CO) followed by the addition of acetonitrile to precipitate plasma proteins. The column was eluted under vacuum, and the extracts were analyzed using a Waters Alliance 2795 Liquid Chromatograph (LC) coupled to a Micromass Quattro micro triple quadrupole MS equipped with a MASSLYNX data acquisition system (Micromass Inc., Manchester, United Kingdom). LC separation was achieved using a Phenomenex Synergi Max-RP, 2.0 3 20 mm, 2-lm particles at 35°C, and mobile phase of 50mM ammonium acetate and acetonitrile at a flow rate of 0.25 ml/min. The MS was operated in the negative ionization mode with a capillary voltage of 2.8 kV, a cone voltage of 15 V, and a source temperature of 130°C. The analytes of interest were quantitated in multiple responsemonitoring mode with transitions of m/z 413/369 for PFO and 477/393 for 8-2 FTA.
Urine sample preparation and metabolite identification. Urine samples from rats in the oral dose experiments were pooled through 90% of the total radioactive dose eliminated over the 168-h collection period and filtered (0.45 lm), and representative samples were analyzed by liquid chromatography-accurate radioisotope counting (LC-ARC) and LC-MS.
Feces sample preparation and metabolite identification. Feces samples from rats in the oral dose experiment were pooled through 90% of the total radioactive dose eliminated via the feces, and aliquots solvent was extracted using an accelerated solvent extraction system (Dionex Corporation, Sunnyvale, CA) with repeat cycles of 75:25 acetonitrile:water and 75:25 methanol:water at 100°C and 1500-2000 psi. The final extract was filtered (0.45 mm) and analyzed by LC-ARC and LC-MS. Extraction of radioactivity exceeded 80%.
Bile sample preparation and metabolite identification. Bile samples from rats in the biliary elimination experiment were pooled through 90% of the total radioactive dose eliminated via the bile, and samples (200 ll) were filtered (0.45 lm) and mixed with 2M potassium chloride and 1M ammonium acetate. The sample was then partitioned with hexane, the aqueous phase isolated, and a selected representative sample was submitted for LC-ARC and LC-MS analysis.
Plasma sample preparation and metabolite identification. Serial plasma samples collected from a single male rat (supplemental experiment) at 1, 2, 4, 8, and 24 h were pooled, precipitated with acetonitrile, centrifuged, filtered (0.45 lm), and submitted for LC-MS analysis.
Liquid chromatography-accurate radioisotope counting. Representative samples of urine, feces extract, and bile extract were quantitatively analyzed using a Hewlett-Packard 1100 Series ChemStation. Separation was achieved using a FluroFlash 4.6 mm 3 150 mm column (Fluorous Technologies, Pittsburgh, PA) and a gradient of 0.15% acetic acid in water and methanol with a flow rate of 1 ml/min (ambient temperature). Column effluent was mixed with StopFlow AQ, High Efficiency Liquid Scintillation Cocktail (AIM Research Co., Newark, DE), followed by radiodetection using a Radiomatic 150TR Series FLO-One System/LC-ARC system (AIM Research Co.), containing a 1300-ll flow cell, stopping effluent flow in the liquid cell every 10 s, with a hold time for counting of 2 min. For each injection, the regions of interest were identified and integrated. Based on the total radioactivity injected on column, the percentage of total dose administered represented by each integrated region of interest was determined (percentage of dose). Recovery of the on-column injection of radioactivity was > 90%.
Individual metabolites (regions of interest identified by LC-ARC) from urine, feces, and bile were isolated by fraction collection in a repeat LC run and the isolated fractions submitted for mass spectral analysis.
Liquid chromatography-mass spectral analysis. Samples of urine (both neat samples and fractions representing isolated peaks of interest), feces extract, bile extract, plasma extract, and hepatocyte extract solution, along with matrix control samples were screened using a Waters Alliance 2790 LC coupled to a Micromass QToF II hybrid quadrupole/time-of-flight MS, operated in negative electrospray ionization mode, equipped with a MASSLYNX data acquisition system (Micromass Inc.). Separation was achieved using a Zorbax SB-C 18 RP, 2.1 3 150 mm, 5-lm particle size, a gradient mobile phase of 0.15% acetic acid and methanol (urine only) and 2mM ammonium acetate and methanol, at a flow rate of 0.3 ml/min. The MS system was operated with a capillary voltage of 0.8-2.9 kV, a cone voltage of 16-24 V, a source temperature of 125°C, and a desolvation temperature of 350°C.
Data presentation and statistical analyses. The calculated values presented in the tables for the oral and dermal material balance experiments were generated by Debra v.5.1a (LabLogic Systems Ltd., Sheffield, United Kingdom). The statistical significance of selected data was assessed by the Student's t-test using Microcal, version 7.0 (OriginLab Corporation, Northampton, MA). A p value of 0.05 was considered significant.
Noncompartmental pharmacokinetic parameters for plasma total radioactivity, 8-2 FTOH, PFO, and 8-2 FTA were generated using WinNonlin ver. 4.0, Pharsight Corporation (Mountain View, CA). Calculated parameters included ABSORPTION, DISTRIBUTION, METABOLISM, AND ELIMINATION OF 8-2 FLUOROTELOMER ALCOHOL IN THE RAT time to maximum plasma concentration (T max ) in hours; maximum plasma concentration observed (C max ) in ng equiv/ml (for total radioactivity) or ng/ml (for 8-2 FTOH, PFO, and 8-2 FTA); area under the concentration-time curve to infinity (AUC inf ) in hÁng equiv/ml (for total radioactivity), and hÁng/ml (for 8-2 FTOH, PFO, and 8-2 FTA); and the terminal elimination half-life (t 1/2 ) in hours. Plasma PFO concentration data after 48 h for female rats at the 125-mg/kg dose level were excluded due to questionable results. The lowest standard concentration for determining the plasma concentrations of 8-2 FTOH, PFO, and 8-2 FTA was 0.005 lg/ml (5 ng/ml) and was assumed to be equal to the limit of quantitation (LOQ).
RESULTS

Oral Dosing, Material Balance, and Biliary Elimination
Following a single oral dose of [3-14 C] 8-2 FTOH to male and female rats at 5 and 125 mg/kg and a 168-h collection period, the majority of the administered radioactivity (> 70%) was excreted in the feces, exclusive of sex and dose level ( Table 1) . Excretion of radioactivity via the urine was a minor pathway, with approximately 2.1-to 2.4-fold more total radioactivity recovered in female urine (2.7-3.6%) compared to male urine (1.3-1.5%). Recovery of the administered radioactive dose was > 76%.
Following a 5-mg/kg single oral dose of [3-14 C] 8-2 FTOH, 39 and 45% of the dose was eliminated via the bile in male and female rats, respectively, as compared to 21 and 19% at the 125-mg/kg dose level. Total systemic absorption of 8-2 FTOH (calculated as the sum of the percent administered 14 C dose recovered in urine, tissues, and bile) was estimated to be 49 and 57% at 5 mg/kg, and 27 and 27% at 125 mg/kg for male and female rats, respectively.
Owing to the high amount of radioactivity eliminated via the feces, the semivolatile character of 8-2 FTOH, and its low miscibility in water (Krusic et al., 2005) , it was hypothesized that by allowing the feces samples to thaw at room temperature for processing and blending with water prior to sample oxidation, a portion of the radioactive 8-2 FTOH volatilized and was lost, which resulted in the low recovery of radiolabeled 8-2 FTOH from rats in the high (and likely the low) oral dose groups. To test this hypothesis an additional rat per sex was dosed at 125 mg/kg, and the feces was maintained frozen on dry ice and oxidized completely to minimize the potential loss of radioactivity. The results of this experiment showed an increase in the amount of radioactivity recovered in the feces (~5-13%) with an overall recovery of > 90%, confirming the hypothesis.
Overall, and for the vast majority of tissues, the mean concentration of radioactivity was greater than whole blood at 168 h following an oral dose of [3-14 C] 8-2 FTOH ( Table 2) . For both male and female rats, fat, liver, adrenals, and thyroid contained the greatest 14 C concentrations at terminal sacrifice. 
Oral Dosing and Plasma Kinetics
Following oral dosing, total radioactivity, parent 8-2 FTOH, and each of the quantitated metabolites appeared rapidly in the plasma of both sexes and at both dose levels (Fig. 1) . T max was 3.8 h for all metabolites except PFO (Table 3) . C max for total radioactivity, the parent telomer alcohol, and each analyte by dose level were comparable between the sexes (less than twoto threefold difference), with the exception of 8-2 FTA at the low dose, which was approximately fivefold higher in female rats. Clearance of 8-2 FTOH and 8-2 FTA was rapid in both sexes and at both dose levels as indicated by the relatively short plasma t 1/2 of approximately 1-5 h for 8-2 FTOH and 4-18 h for 8-2 FTA. The internal dose to parent 8-2 FTOH, as measured by AUC inf , was similar for male and female rats by dose level (less than or equal to twofold difference), which increased in a dose-dependent fashion for both sexes. However, in male rats, there was less than a 15-fold increase in AUC inf with a 25fold increase in dose. For PFO, several possibly erroneous plasma concentrations after 48 h made the kinetic parameter calculations more difficult to resolve. PFO plasma concentrations in the high-dose females dropped to below the LOQ after 24 h. However, several later time points actually had quantifiable concentrations of PFO. The reason for this is unclear, but with the majority of plasma PFO concentrations < LOQ after 24 h, all concentrations were assumed to be < LOQ after 48 h for the calculation of pharmacokinetic parameters.
The t 1/2 for PFO was longer in males (112-217 h) than in female rats (5.6-17.5 h) at both dose levels. At the 125-mg/kg dose level, the t 1/2 for PFO in males was calculated to be 112 h. Nondetectable concentrations were ignored at the 120-h time point, lessening confidence in this value. Internal dose for PFO was correspondingly higher in males at both dose levels consistent with previous PFO pharmacokinetic studies (Kemper and Jepson, 2003; Vanden Heuvel et al., 1991) . With the exception of the PFO t 1/2 for male rats at the low-dose level (217 h), the PFO t 1/2 was less than the t 1/2 for total radioactivity, indicating that another metabolite (or metabolites) present in the plasma but not quantitated was responsible for the total radioactivity terminal elimination half-life.
Total radioactivity internal exposure and elimination were significantly different from parent 8-2 FTOH. On average, the total radioactivity AUC inf was 580-to 680-fold and 170-to 200-fold higher than the 8-2 FTOH AUC inf for male and female rats, respectively. Exclusive of sex, 8-2 FTOH t 1/2 was < 5 h while t 1/2 for total radioactivity was much longer (68-216 h). The total radioactivity AUC inf was much greater than the sum of the AUC inf values for the measured metabolites in the plasma, suggesting that another metabolite or metabolites were present in the plasma. This disparity, when represented as a percentage of the total radioactivity AUC inf at each dose level (sum of the individual analyte AUC inf values divided by the total radioactivity AUC inf 3 100), was greater for females (3.4-9.4%) than males (25-26%) primarily due to the correspondingly higher concentrations of PFO in the plasma of male rats.
Dermal Exposure
Following a 6-h dermal exposure to [3-14 C] 8-2 FTOH at 125 mg/kg and a collection period of 168 h, excretion via urine (< 0.1%) and feces (< 0.2%) was minor, indicating that systemic absorption of 8-2 FTOH from topical administration was negligible (Table 4 ). The majority of the applied radioactive dose for both male and female rats was either retained in the organic volatile trap (> 37%) or was washed from the application skin site (> 29%). Total recovery of the 14 C dose was > 68%. On average, tissues taken at terminal sacrifice did not contain detectable concentrations of radioactivity (< LOD), and this was with few exceptions. Based on the average amount of 8-2 FTOH applied (~31,250 lg), total radioactive residues at terminal sacrifice were detected at the site of application (21-58 lg equiv/g), the fat (0.25-0.36 lg equiv/g), and liver (0.09-0.24 lg equiv/g). The total absorbed dose following a single 6-h dermal exposure and a 7-day recovery collection period was low ranging from 0.5 to 1% and was primarily due to the radioactivity that remained at the application site. 
Metabolite Identification
A comprehensive list of metabolites identified in urine, bile, feces, and plasma following a single oral dose of 8-2 FTOH to rats, along with observed fragment ions, is presented in Table 5 .
Urine metabolites. LC-ARC analysis of urine following oral dosing showed an initial peak, identified by mass spectral analysis as PFO, which eluted near the solvent front ( Fig. 2a ). Elution of PFO with the solvent front likely resulted from channeling within the FluroFlash column due to the large injection volume used to detect the low-concentration metabolites. Column-retained PFO eluted at approximately 31 min. Of the urinary metabolites resolved via fraction collection and mass spectral analysis, PFO concentrations, which included unretained PFO, were highest (~25% of urinary metabolites), accounting for approximately 0.48 and 1.16% of the administered 14 C dose, at the high-and low-dose levels, respectively. The second LC-ARC peak (Unknown-1) daughter ion mass spectrum (m/z 429) contained two fragment ions, m/z 253 and m/z 176; the loss of 176 amu is diagnostic for glucuronide conjugates. However, given the proposed mass, this conjugate of undetermined structure would not possess the radiolabel so the actual radiolabeled metabolite associated with this LC-ARC response is not known. Coeluting perfluorohexanoate (PFHx) and 5-2 FTOH (Unknown-2) and 7-2 (secondary) FTOH glucuronide (7-2 sFTOHÁGluc) were identified in fractions from the pooled sample and accounted for < 0.5% of the administered dose. Since neither the six-carbon PFHx nor the 5-2 FTOH would contain the 14 C radiolabel (position 3 of 8-2 FTOH), the LC-ARC response was likely due to an unstable metabolite not detected by LC-MS ( Fig. 2a) . Reanalysis of the urine pool 2 months subsequent to the initial evaluation and following a number of freeze-thaw cycles confirmed the loss of two peaks, one associated with the (14) 117 (61) 170 (102) 852 (198) AUC inf (hÁng/ml) 7.6 3 10 4 (1.5 3 10 4 ) a 2.4 3 10 4 (1.2 3 10 3 ) a 1.3 3 10 2 (0.37 3 10 2 ) 1.4 3 10 2 (1.0 3 10 3 ) 2.6 3 10 4 (1.8 3 10 4 ) 4.4 3 10 2 (1.5 3 10 2 ) 6.0 3 10 2 (3.5 3 10 2 ) 1.7 3 10 3 (0.45 3 10 3 ) t 1/2 (h) 101 (23) 1.3 3 10 6 (6.2 3 10 4 ) b 7.6 3 10 5 (4.1 3 10 5 ) b 1.9 3 10 3 (0.6 3 10 3 ) 3.7 3 10 3 (1.9 3 10 3 ) 3.2 3 10 5 (1.2 3 10 4 ) 8.8 3 10 3 (2.8 3 10 3 ) c 1.2 3 10 4 (0.5 3 10 4 ) 1.3 3 10 4 (0.6 3 10 4 ) t 1/2 (h) 216 (38) isolated fraction containing PFHx and 5-2 FTOH and the other the last unidentified peak in the initial LC-ARC profile. This confirmed that at least two metabolites observed in the initial LC-ARC profile were not detected in subsequent analysis either because they had volatilized or degraded or they could not be detected by LC-MS. Additional and preliminary follow-up experiments with urine incubated with 2,4-dinitrophenylhydrazine, with GC-MS analysis not previously attempted in any experiments, revealed the presence of a fluorotelomer aldehyde tentatively identified as 7-3 unsaturated FTAL (7-3 uFTAL), which could account for the loss of at least one of the original metabolites observed in urine. The 5-2 FTOH was probably a contaminant in the starting technical or radiolabeled 8-2 FTOH source materials. However, the 7-carbon 5-2 FTOH was not detected in the neat starting materials by GC-MS characterization, and so its source remains unresolved. The 7-2 sFTOHÁGluc, a minor metabolite in these studies (< 0.5% of the administered dose), has been previously reported as a primary metabolite in activated sludge (Wang et al., 2005a) . Other minor metabolites identified by the LC-ARC chromatogram (< 0.1% of the administered dose) were not resolved by LC fraction collection and subsequent LC-MS identification.
Mass spectral analysis of a neat, pooled urine sample, using a Zorbax C 18 column with a similar mobile-phase composition as was used with the FluroFlash column, demonstrated the presence of similar metabolites as was observed with LC-ARC (Fig. 2b ). An MS-only screening process allowed for identification of metabolites lacking the radiolabel (position 3 on the parent molecule), allowing for a more comprehensive evaluation of the metabolism of 8-2 FTOH.
Bile metabolites. The LC-ARC profiles of pooled bile from either oral dose level revealed the presence of three principal, late-eluting peaks at 35-40 min, independent of sex. LC-MS analysis of isolated peaks of interest was unsuccessful. However, LC-MS analysis of a representative neat bile sample (Fig. 3) , which was qualitatively similar to the LC-ARC profiles, identified the metabolites m/z 744, 730, and 639, which were proposed to be the GSH conjugate of the 8-2 FTUA, the GSH conjugate of the 8-2 uFTOH, and the glucuronide conjugate of the parent 8-2 FTOH, respectively. The negative electrospray ionization MS responses for these metabolites were too weak to obtain daughter ion mass spectra. However, the mass spectra for these metabolites compared with those confirmed by MS-MS from the rat hepatocyte experiment (Fig. 4) provide confidence in the structure assignment for these three biliary metabolites (Fig. 5) .
Based on the total radioactivity eliminated via the bile, these three conjugates represented approximately 42 and 20% of the administered 14 C dose or approximately 79 and 74% of the absorbed dose for the low and high oral dose groups, respectively.
Fecal metabolites. The LC-ARC profiles of extracts from pooled feces from either oral dose level revealed the presence of a number of late-eluting peaks, dominated by a single, highly organic-soluble peak. Radiochromatograms were comparable between males and females and were independent of represented the greatest percentage of the administered dose (20-38%) and a significant portion of the radioactivity burden in the feces (51-80%). The more polar minor metabolites (Fig. 6) were tentatively identified as the cysteine (m/z 558) and cysteinylglycine conjugates (m/z 615) of 8-2 FTUA and the cysteine and cysteinylglycine conjugate of 8-2 uFTOH, m/z 544 and m/z 601, respectively.
Plasma metabolites. Overlaid LC-MS-negative single-ion chromatograms for a representative plasma sample are presented in Figure 7 . Although the signal strength for the earliest eluting component (m/z 313) was too weak for MS-MS analysis, in-source fragmentation during full-scan analysis indicated the loss of CO 2 , consistent with the structure of PFHx. Perfluoroheptanoate (PFHp), an odd-numbered perfluorinated acid, was also observed (m/z 363) in plasma. The most abundant plasma metabolite, assuming equivalent MS response, was PFO (m/z 413). Numerous low-concentration metabolites (m/z 445, 463, 439, 457, and 477) were also detected in the plasma, and the trace peak, m/z 463, was proposed to be the odd-numbered PFN. Although the mass spectral response for PFN was too low for structure confirmation by MS-MS, in-source fragmentation supports this structural assignment (the fragment ion m/z 420 is consistent with eight perfluorinated carbons). The final metabolite, m/z 441, was the second most abundant metabolite in plasma and possibly the principal metabolite accounting for the majority of the unquantified plasma metabolite burden. The daughter ion mass spectrum of this metabolite was consistent with the structure for the metabolite 7-3 Acid, showing responses at m/z 337 and 317 indicating successive losses of hydrogen fluoride (HF).
DISCUSSION
[3-14 C] 8-2 FTOH Recovery and Distribution
In oral dosing pilot experiments with [3-14 C] 8-2 FTOH in the rat at 125 mg/kg using a closed-system environment, approximately 0.3% of the administered radioactive dose was eliminated as organic volatiles, with barely detectable concentrations of 14 CO 2 (< 0.1%). Based on these initial results, collection of 14 C-organic volatiles and 14 CO 2 was excluded from the main study experiments, consistent with standard ADME practice (USEPA, 1998) . Following oral administration of radiolabeled 8-2 FTOH to male and female rats in the main study experiments, 34-50% of the parent 8-2 FTOH transited the gastrointestinal (GI) tract unmetabolized and was eliminated in the feces. It is plausible that the actual amount of unmetabolized parent may have been higher, particularly at the 125-mg/kg dose level, since radiolabeled 8-2 FTOH was shown to have been lost from the feces during sample processing due to its volatility and low water solubility.
Only a small portion of the total radioactivity in the administered oral dose was retained in the tissues after 7 days following a 5-mg/kg (7%) or 125-mg/kg (4.4%) single oral 8-2 FTOH dose. The percentage of dose associated with the fat at 168 h, based on a body weight of 200 g, and USEPA's (1994) relationship for total body fat as a function of body weight, was estimated to be 1.2-1.4% (male) and 2.1-2.8% (female) at the low-and high-dose levels, respectively. In pilot experiments, attempts were made to resolve the character of the radioactivity in fat, which contained the highest radioactivity residues at 168 h postdose. However, LC-ARC analysis of an ethanolwater (vol/vol) extract from a representative sample proved unsuccessful. An additional evaluation of the extract by LC-MS revealed the presence of short-chain perfluorinated acids (PFHx and PFHp), including PFO and PFN, independent of sex, but these perfluorinated acids were also observed in fat from a control sample. Clearly, more work is needed to clarify and confirm the presence of these perfluorinated acids in selected tissues and whether or not their presence is due to exposure to and metabolism of 8-2 FTOH.
Dermal exposure to [3-14 C] 8-2 FTOH in vivo resulted in significant amounts of the applied dose volatilizing from the skin surface during the exposure and being removed by washing (68-72%). Efforts to increase the recovery of the applied [3-14 C] 8-2 FTOH dose were improved by the use of ethanol instead of a soap and water solution to wash the skin at the end of the 6-h exposure; pilot experiments where a 2% soap and water solution was used resulted in unacceptable recoveries (< 40%), which increased significantly with the unconventional use of ethanol. Based on recent in vitro dermal experiments conducted at DuPont (DuPont-6997, unpublished) using rat and human skin mounted in a static diffusion cell model and a 6-h exposure to [3-14 C] 8-2 FTOH in an ethanol vehicle, a conservative model for exposure to neat 8-2 FTOH total absorption was~50% and~30% for rat and human skin, respectively. In vitro dermal absorption of 8-2 FTOH from a 0.5% methylcellulose vehicle was much lower for human skin (~7%). Based on the in vitro (ethanol vehicle) and in vivo dermal experiments, human in vivo exposure to 8-2 FTOH would probably result in < 1% absorption with a majority of the absorbed dose becoming sequestered within the stratum corneum, which would eventually be lost by normal desquamation (Reddy et al., 2000; Roberts and Walters, 1998; Schaefer and Redelmeier, 1996) .
8-2 FTOH Metabolic Pathway in the Rat
A proposed metabolic pathway for 8-2 FTOH in the rat, which consists of a conjugate route and a degradation route, is presented in Figure 8 .
The conjugate metabolic pathway involves direct conjugation of parent with glucuronic acid. Although the supporting in vitro experiments with rat hepatocytes suggest that 8-2 FTOH may also be conjugated to sulfate, no sulfate conjugates were identified in the rat in vivo oral dosing studies. A second conjugate pathway involves sequential metabolism of 8-2 FTOH to 8-2 FTAL, elimination of HF to form the unsaturated aldehyde (8-2 uFTAL), conjugation of 8-2 uFTAL with GSH, and finally reduction of the unsaturated aldehyde conjugate to 8-2 uFTOHÁGS. The 8-2 uFTOHÁGS conjugate was apparently further degraded by enzymes of the mercapturic acid pathway yielding the cysteinylglycine (8-2 uFTOHÁS-CysGly) and cysteine conjugates (8-2 uFTOHÁSCys). The mercapturate, N-acetylated 8-2 uFTOH cysteine conjugate (8-2 uFTOHÁSCysNAcetyl), which was preferentially eliminated in urine and likely formed via 8-2 uFTOHÁSCys, facilitated by N-acetyltransferase, could either be converted back to the deacetylated form via a deacetylatase (DA) or directly acted upon by cysteine conjugate b-lyase (CCbL) to yield 8-2 uFTOH 3-thiol, although the 8-2 uFTOH 3-thiol metabolite was not identified in the current investigation. Additionally, 8-2 FTUAÁGS and its degradation products (8-2 FTUAÁSCysGly, 8-2 FTUAÁSCys, and 8-2 FTUAÁSCysNAcetyl) were detected in bile and feces, respectively. The 8-2 FTUAÁSCysNAcetyl The first steps in the degradation metabolic pathway are oxidation of 8-2 FTOH to 8-2 FTA by the sequential action of alcohol dehydrogenase or P450 and aldehyde dehydrogenase, with 8-2 FTAL as a transient intermediate. 8-2 FTUA was formed by dehydrofluorination of 8-2 FTA and is likely a key branching point in the degradation metabolic pathway. In the first branch, 8-2 FTUA undergoes reduction and dehydrofluorination yielding 7-3 uAcid, which was identified in plasma; 7-3 Acid can be formed by reduction of 7-3 uAcid and was a stable metabolite observed in these studies and previous microbial degradation experiments (Wang et al., 2005b) . Both the saturated and unsaturated 7-3 Acids may enter the mitochondrial fatty acid b-oxidation pathway generating PFO. A second degradation branch is proposed to lead to the formation of 7-2 sFTOH, a primary metabolite identified in microbial cultures from either 8-2 FTUA or 7-3 uAcid, via the intermediates 8-1 Olefin and 7-2 Olefin (Wang et al., 2005b) . A glucuronide conjugate of 7-2 sFTOH (7-2 sFTOHÁGluc) was observed in urine from rats in the current in vivo oral dosing experiment and supports the formation of the secondary alcohol precursor.
Most interesting is the observation of several perfluorocarboxylates with less than eight carbons but no shorter than five carbons. These metabolites indicate mammalian metabolism pathways that resulted in multiple CF 2 groups transforming, a finding not previously reported. The formation of trace amounts of odd-numbered perfluorocarboxylates has been reported to occur in activated wastewater sludge following incubation with 8-2 FTOH (Pace Project CA085, 2002) . Formation of PFN from 8-2 FTA could occur via a-oxidation; a-oxidation in mammals has been previously reported for phytanic acid, a branchedchain fatty acid (Casteels et al., 2003; Wanders et al., 2003) , and 2-hydroxyoctadecanoic acid, a straight-chain 2-hydroxyfatty acid (Foulon et al., 2005) . Nonetheless, the metabolic pathways involved in the formation of the even-numbered (PFHx, PFO) and odd-numbered perfluorocarboxylates (perfluoropentanoate, which was observed in rat hepatocytes, and PFHp and PFN) warrant additional investigation.
The Relationship between 8-2 FTOH Metabolism and
Toxicity in the Rat following Subchronic Exposure
In the rat, metabolism of 8-2 FTOH involved dehydrofluorination. These dehydrofluorination metabolic steps likely resulted in excess concentrations of fluoride in plasma at 125 mg/kg/day (~200-460 ng/ml) compared to controls (~100 ng/ ml) following subchronic exposure unpublished) and caused the toxicologically significant degenerationdisorganization of enamel organ ameloblasts cells; high urinary fluoride concentrations were also noted in the 90-day study. The tooth lesion, along with the increased incidence of striated teeth, was concluded to be consistent with fluoride toxicosis (Reddy and Hayes, 1989) .
Since only a minor portion of the parent FTOH was converted to perfluorinated acids and a majority was metabolized to 8-2 FTUAÁGS and the 8-2 uFTALÁGS with subsequent reduction to 8-2 uFTOHÁGS, depletion of hepatic and extrahepatic GSH stores, precipitating an accumulation of 8-2 uFTAL and 8-2 FTUA, may possibly account for some of the lesions observed in the liver following repeated exposures to 8-2 FTOH and FTOH mixtures (DuPont-9478, unpublished; Ladics et al., 2005) . In light of a lack of supporting adverse changes in clinical chemistry parameters, the mechanisms for the renal tubule lesions observed following subchronic exposure to 8-2 FTOH remain speculative unpublished) . However, it 352 FASANO ET AL. seems plausible that the reported cortical tubule hypertrophy may have been initiated by 8-2 uFTOH 3-thiol and/or 8-2 FTUA 3-thiol, the respective degradation products of the 8-2 uFTOHÁSCys and 8-2 FTUAÁSCys, mediated by CCbL, which is a well-described pathway for production of nephrotoxic thiol and thioketene metabolites from GSH conjugates (Elfarra and Anders, 1984; Green et al., 2003; Lash et al., 1986 Lash et al., , 1998 Lash et al., , 2002 .
Recently, Kudo et al. (2005) reported a dose-dependent increase in liver weights accompanied by peroxisome proliferation in mice administered 8-2 FTOH in diet. The observed gross pathology and biochemical changes correlated with PFO (not PFN) concentrations in the liver. Induction of peroxisomal b-oxidation by PFCAs is well documented (Borges et al., 1992; Harrison et al., 1988; Kawashima et al., 1995; Kudo et al., 2000) . Even though liver PFO concentrations were not determined in the current 8-2 FTOH ADME experiments, the plasma kinetic results did suggest that PFO clearance was delayed in male rats at the 125-mg/kg dose level and thus likely to be present in the liver. Kemper and Jepson (2003) demonstrated that PFO concentrations were generally higher in liver compared to plasma following oral administration of ammonium perfluorooctanoic acid. These observations, along with the hepatic peroxisome proliferation observed at 125 mg/kg/day in male rats following a 90-day dosing period and a 3-month recovery phase unpublished) , suggest that PFO may be partly responsible for the observed hepatic toxicity.
In summary, the studies and results described here provide a more comprehensive picture of 8-2 FTOH ADME in the rat FIG. 8. Proposed metabolic pathway for 8-2 FTOH in the rat. Conjugate pathway: UDP-glucuronosyltransferase (UDPGT); sulfotransferase (SULT); glutathione-S-transferase (GST); deacetylase (DA); N-acetylase (NAT); cysteine conjugate b-lyase (CCbL). Degradation pathway: alcohol dehydrogenase (ADH); aldehyde dehydrogenase (ALDH). ABSORPTION, DISTRIBUTION, METABOLISM, AND ELIMINATION OF 8-2 FLUOROTELOMER ALCOHOL IN THE RAT than has been previously reported. Additional studies will be required to refine the biotransformation pathways for 8-2 FTOH and to clarify the link between 8-2 FTOH metabolism and toxicity in the rat.
